(2005). A: Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
(1984). Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature
(2007). AE: Mouse skin chemical carcinogenesis is inhibited by antizyme in promotion-sensitive and promotion-resistant genetic backgrounds. Mol Carcinog
(1995). al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity
(1999). al: Safety and antitumor activity of recombinant soluble Apo2 ligand.
(1999). Alnemri ES, El-Deiry WS: Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res
(1997). Alnemri ES: Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL.
(2010). Ashkenazi A: New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene
(1986). Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature
(2000). Chambon P: Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis. Nature
(2010). Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature
(2007). Chiao PJ, et al: Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAILinduced death. Cancer Cell
(2010). Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells? Cell Mol Life Sci
(2011). Critical role for tumor necrosis factor-related apoptosisKedinger et al. Molecular Cancer